The DLK1⁻DIO3 region contains a large miRNA cluster, the overexpression of which has previously been associated with myelodysplastic syndromes (MDS). To reveal whether this overexpression is epigenetically regulated, we performed an integrative analysis of miRNA/mRNA expression and DNA methylation of the regulatory sequences in the region (promoter of the MEG3 gene) in CD34+ bone marrow cells from the patients with higher-risk MDS and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), before and during hypomethylating therapy with azacytidine (AZA). Before treatment, 50% of patients showed significant miRNA/mRNA overexpression in conjunction with a diagnosis of AML-MRC. Importantly, increased level of MEG3 was associated with poor outcome. After AZA treatment, the expression levels were reduced and were closer to those seen in the healthy controls. In half of the patients, we observed significant hypermethylation in a region preceding the MEG3 gene that negatively correlated with expression. Interestingly, this hypermethylation (when found before treatment) was associated with longer progression-free survival after therapy initiation. However, neither expression nor methylation status were associated with future responsiveness to AZA treatment. In conclusion, we correlated expression and methylation changes in the DLK1⁻DIO3 region, and we propose a complex model for regulation of this region in myelodysplasia.

General University Hospital 128 08 Prague Czech Republic

Institute of Hematology and Blood Transfusion U Nemocnice 1 128 20 Prague 2 Czech Republic

Zobrazit více v PubMed

Aul C., Bowen D.T., Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71–86. PubMed

Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2014;89:97–108. doi: 10.1002/ajh.23642. PubMed DOI

Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., Schoch R., Gattermann N., Sanzet G., List A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232. doi: 10.1016/S1470-2045(09)70003-8. PubMed DOI PMC

Kornblith A.B., Herndon J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., Powell B.L., De Castro C., Ellerton J., Larson R.A., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J. Clin. Oncol. 2002;20:2441–2452. doi: 10.1200/JCO.2002.04.044. PubMed DOI

Vardiman J., Reichard K. Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Am. J. Clin. Pathol. 2015;144:29–43. doi: 10.1309/AJCP58RSMFRHLHHH. PubMed DOI

Loiseau C., Ali A., Itzykson R. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Exp. Hematol. 2015;43:661–672. doi: 10.1016/j.exphem.2015.05.014. PubMed DOI

Benetatos L., Hatzimichael E., Londin E., Vartholomatos G., Loher P., Rigoutsos I., Briasoulis E. The microRNAs within the DLK1-DIO3 genomic region: Involvement in disease pathogenesis. Cell. Mol. Life Sci. 2013;70:795–814. doi: 10.1007/s00018-012-1080-8. PubMed DOI PMC

Kagami M., O’Sullivan M.J., Green A.J., Watabe Y., Arisaka O., Masawa N., Matsuoka K., Fukami M., Matsubara K., Kato F., et al. The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: Hierarchical interaction and distinct functional properties as imprinting control centers. PLoS Genet. 2010;6:e1000992. doi: 10.1371/journal.pgen.1000992. PubMed DOI PMC

Rosa A.L., Wu Y., Kwabi-Addo B., Coveler K.J., Reid Sutton V., Shaffer L.G. Allele-specific methylation of a functional CTCF binding site upstream of MEG3 in the human imprinted domain of 14q32. Chromosome Res. 2005;13:809–818. doi: 10.1007/s10577-005-1015-4. PubMed DOI

Formosa A., Markert E.K., Lena A.M., Italiano D., Finazzi-Agro’ E., Levine A.J., Bernardiniet S., Garabadgiual A.V., Melino G., Candi E. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33:5173–5182. doi: 10.1038/onc.2013.451. PubMed DOI

Niu C.S., Yang Y., Cheng C. MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int. J. Oncol. 2013;42:1533–1540. doi: 10.3892/ijo.2013.1844. PubMed DOI PMC

Jin Y., Peng D., Shen Y., Xu M., Liang Y., Xiao B., Lu J. MicroRNA-376c inhibits cell proliferation and invasion in osteosarcoma by targeting to transforming growth factor-alpha. DNA Cell Biol. 2013;32:302–309. doi: 10.1089/dna.2013.1977. PubMed DOI

Choong M.L., Yang H.H., McNiece I. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp. Hematol. 2007;35:551–564. doi: 10.1016/j.exphem.2006.12.002. PubMed DOI

Tenedini E., Roncaglia E., Ferrari F., Orlandi C., Bianchi E., Bicciato S., Tagliafico E., Ferrari S. Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoiesis: Role of hsa-mir-299-5p in CD34+ progenitor cells commitment. Cell Death Dis. 2010;1 doi: 10.1038/cddis.2010.5. PubMed DOI PMC

Wang F., Yu J., Yang G., Wang X., Zhang J. Regulation of erythroid differentiation by miR-376a and its targets. Cell Res. 2011;21:1196–1209. doi: 10.1038/cr.2011.79. PubMed DOI PMC

Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J.M., Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111:5078–5085. doi: 10.1182/blood-2008-01-133355. PubMed DOI

Valleron W., Laprevotte E., Gautier E., Quelen C., Demur C., Delabesse E., Agirre X., Prósper F., Kiss T., Brousset P. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia. 2012;26:2052–2060. doi: 10.1038/leu.2012.111. PubMed DOI

Ley T.J., Miller C., Ding L., Raphael B.J., Mungall A.J., Robertson A.G., Hoadley K., Triche T.J., Laird P.W., Baty J.D., et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013;368:2059–2074. PubMed PMC

Dixon-McIver A., East P., Mein C.A., Cazier J., Molloy G., Chaplin T., Lister T.A., Young B.D., Debernardi S. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS ONE. 2008;3:e2141. doi: 10.1371/journal.pone.0002141. PubMed DOI PMC

Votavova H., Grmanova M., Merkerova M.D., Belickova M., Vasikova A., Neuwirtova R., Cermak J. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J. Hematol. Oncol. 2011 doi: 10.1186/1756-8722-4-1. PubMed DOI PMC

Merkerova M.D., Krejcik Z., Votavova H., Belickova M., Vasikova A., Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur. J. Hum. Genet. 2011;19:313–319. doi: 10.1038/ejhg.2010.209. PubMed DOI PMC

Krejčík Z., Beličková M., Hruštincová A., Kléma J., Zemanová Z., Michalová K., Čermák J., Jonášová A., Merkerová M.D. Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment. Cancer Genet. 2015;208:156–161. doi: 10.1016/j.cancergen.2015.03.003. PubMed DOI

Merkerova M.D., Krejcik Z., Belickova M., Hrustincova A., Klema J., Stara E., Zemanova Z., Michalova K., Cermak J., Jonasova A. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. Eur. J. Haematol. 2015;95:35–43. doi: 10.1111/ejh.12458. PubMed DOI

Manodoro F., Marzec J., Chaplin T., Miraki-Moud F., Moravcsik E., Jovanovic J.V., Wang J., Iqbal S., Taussig D., Grimwade D., et al. Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood. 2014;123:2066–2074. doi: 10.1182/blood-2012-12-469833. PubMed DOI

Benetatos L., Hatzimichael E., Dasoula A., Dranitsaris G., Tsiara S., Syrrou M., Georgiou I., Bourantas K.L. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk. Res. 2010;34:148–153. doi: 10.1016/j.leukres.2009.06.019. PubMed DOI

Merkerova M.D., Bystricka D., Belickova M., Krejcik Z., Zemanova Z., Polak J., Hajkova H., Brezinova J., Michalova K., Cermak J. From cryptic chromosomal lesions to pathologically relevant genes: Integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype. Genes Chromosomes Cancer. 2012;51:419–428. doi: 10.1002/gcc.21927. PubMed DOI

Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., Pinto A., Beran M., de Witte T.M., Stone R.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425. doi: 10.1182/blood-2005-10-4149. PubMed DOI

Cheson B.D., Bennett J.M., Kopecky K.J., Büchner T., Willman C.L., Estey E.H., Schiffer C.A., Doehner H., Tallman M.S., Lister T.A., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 2003;21:4642–4649. doi: 10.1200/JCO.2003.04.036. PubMed DOI

Krejcik Z., Belickova M., Hrustincova A., Votavova H., Jonasova A., Cermak J., Dyr J.E., Merkerova M.D. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia. Cancer Biomark. 2018;22:101–110. doi: 10.3233/CBM-171029. PubMed DOI

Belickova M., Merkerova M.D., Votavova H., Valka J., Vesela J., Pejsova B., Hajkova H., Klemaet J., Cermak J., Jonasova A. Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. Int. J. Hematol. 2016;104:566–573. doi: 10.1007/s12185-016-2058-3. PubMed DOI

Kumaki Y., Oda M., Okano M. QUMA: Quantification tool for methylation analysis. Nucleic Acids Res. 2008;36:W170–W175. doi: 10.1093/nar/gkn294. PubMed DOI PMC

Pennucci V., Zini R., Norfo R., Guglielmelli P., Bianchi E., Salati S., Sacchi G., Prudente Z., Tenedini E., Ruberti S., et al. Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leuk. Lymphoma. 2015;56:492–496. doi: 10.3109/10428194.2014.910661. PubMed DOI

Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br. J. Haematol. 2007;138:3–11. doi: 10.1111/j.1365-2141.2007.06604.x. PubMed DOI

Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes

Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome